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Objectives: The objectives of this study were to examine changes in incidence and 
prevalence of RA between 1990 and 2014, and to explore if there is any geographic 
variation in incidence and prevalence of RA in the UK 
Methods:  
Design Prospective cohort study  
Setting Primary care  
Participants People contributing acceptable data to Clinical Practice Research 
Datalink (CPRD) between 01/01/1990 and 31/12/2014 were included. Read codes  
were used to identify RA cases ≥18 years in age.  
Outcomes Prevalence and incidence rates for each year standardised to the 2014 
population. Region specific incidence and prevalence of RA for the year 2014 
standardized to the overall population.  
Results: The incidence and prevalence of RA was 3.81 per 10,000 person-years and 
0.67% respectively in 2014. The annual incidence of RA reduced by -1.6%(-0.8% to -
2.5%) between 1990 and 2014, with significant joinpoints at 1994 and 2002. The 
prevalence of RA increased by 3.7%(3.2% to 4.1%)/year from 1990 to 2005; and 
reduced by -1.1%(-2.0% to -0.2%)/year between 2005 and 2014. There were 
significant differences in the occurrence of RA throughout different regions of the UK, 
with highest incidence in East Midlands, Yorkshire and Humber; and highest 
prevalence in North East, and Yorkshire and Humber.  
Conclusion: The incidence of RA is decreasing, with a reduction in prevalence in 
recent years. There is significant geographic variation in occurrence of RA in UK. 
Further research is required to identify the reasons underlying this phenomenon so 
that public-health interventions can be designed to further reduce the incidence of RA. 
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Rheumatoid arthritis (RA) is the commonest auto-immune inflammatory arthritis with 
a prevalence of 0.5%-1.0% and an incidence of 24–45/100,000 person-years(1, 2). It 
occurs due to a combination of genetic, environmental and constitutional risk factors, 
but unlike gout and osteoarthritis (OA) paleo-epidemiologic studies do not provide 
convincing evidence that it has been around for longer than a few hundred years(3). 
Moreover, unlike most common complex disorders like type 2 diabetes(4), obesity(5) 
and hypertension(6) whose incidence and prevalence have increased over time, there 
is considerable controversy as to whether the incidence of RA has reduced rather than 
increased. While most studies report a progressive reduction in the incidence of RA in 
the USA, Finland, and Japan (7-12), others have reported either an increasing (13-15) 
or stable incidence (16) in the USA, and Denmark; and Greece respectively . Several 
explanations for reduced incidence of RA including birth-cohort effect (17-19) and 
increased uptake of hormonal contraception(10-12, 20) have been suggested. 
However, the oral contraceptive hypothesis is not supported by all studies(12, 21), and 
the increase in the mean age of incident RA cases observed in cross-sectional studies 
conducted in the same geographic area several decades apart, and used to suggest 
the presence of a birth cohort effect could be explained by an ageing general 
population(17, 18). Moreover, it is difficult to draw definite conclusions on temporal 
trends in the incidence and prevalence of RA as many published studies are relatively 
small (8, 9, 12, 13, 15-17, 19, 21). Thus, it is necessary to revisit the temporal trends 
in epidemiology of RA.  
The overall aim of this study was to explore variations in the incidence and prevalence 
of RA in the UK between 1990 and 2014. The specific objectives were to: [1] provide 
contemporary data on epidemiology of RA; [2] examine changes in prevalence and 
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incidence of RA between 1990 and 2014; and [3] explore whether there is geographic 
variation in occurrence of RA in the UK since this may help explore possible 





Source of data: Data from the Clinical Practice Research Datalink (CPRD) were used. 
CPRD is one of the largest databases of longitudinal medical records from primary 
care. Established in 1987, it contains anonymised healthcare records from over 13 
million individuals and represents 8% of the UK population at any one time. The data 
in CPRD undergoes thorough quality checks and is of reliable research standard with 
a high validity of recorded diagnoses, including a median proportion of cases with a 
confirmed diagnosis of 89% for 183 different conditions including chronic auto-immune 
conditions(22). The study was approved by the Independent Scientific Advisory 
Committee of the Medicines and Healthcare Regulatory Authority, London, UK (Ref: 
15_101R) 
Study population: The study comprised all participants who contributed acceptable 
quality data to the CPRD between 1st January 1990 and 31st December 2014. The 
denominator for prevalence estimation for each calendar year included all individuals 
registered on 1st July of each calendar year with a GP. For the incidence of RA, at-risk 
cohorts for each calendar year were constructed, which comprised all individuals 
registered with up-to-standard practices (practices meeting the specified data entry 
criteria) during the year specified who had never been coded as having RA before the 
latest of current registration date plus 365 days or 1st January of the calendar year 
specified. Person-years of follow-up were calculated from the latest of 1st January or 
the date of current registration plus 365 days to the earliest date of transfer-out, 
incident RA diagnosis, death or 31st December of the specified year. 
Definition of RA:  RA was defined using a previously published Read code list(23). 
This list was modified after discussions among the investigators (rheumatologists (AA, 
MD, C-FK), academic GP with expertise of CPRD research (CDM), statistician (MJG) 
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and epidemiologist (WZ)) to exclude codes for Adult Still's Disease, Adult-onset Still's 
disease and Juvenile ankylosing spondylitis since they are distinct diseases. 
Case definition: Prevalent cases of RA were participants of at least 18 years in age on 
the 1st July of each calendar year who had a medical Read code that has been used 
previously to identify cases with RA(23). Incident cases of RA were those who had no 
medical code for RA prior to the latest of current registration date plus 365 days or 1st 
January of each calendar year but developed RA during that year, and were at least 
18 years of age at the index date. To be eligible as an incident case, participants had 
to have at least 1-year registration prior to the first date of RA diagnosis as this has 
been shown to reduce the risk of prevalent cases being counted as incident cases in 
chronic conditions such as RA(24). To examine whether this period was sufficiently 
long to exclude these potentially prevalent cases, we also classified cases to have at 
least 3-year registration prior to the first date of RA diagnosis in a sensitivity analysis. 
Statistical analysis: Point prevalence of RA on the 1st July of each year was 
calculated and 95% confidence interval (CI) calculated. Incidence rates by year were 
calculated using the number of incident RA cases during that year as the numerator 
and the total person-years occurring during the same year as the denominator. 
Incidence and prevalence rates were stratified by sex. Poisson regression was used 
to examine the association between sex and prevalent and incident RA. 
To determine the trends in prevalence and incidence of RA, age-, sex- and length of 
data contribution-standardised prevalence and incidence of RA were calculated for 
each calendar year from 1990 to 2013 with the population structure in year 2014 as 
reference. Ten year age-bands were selected for age stratification. The incidence and 
prevalence were standardized for the length of data contribution, as the longer the 
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period a person contributes data to the CPRD the greater the chance that a chronic 
health event will be recorded at some point. The length of data contribution of each 
patient was defined as the period from the current date of registration to the 1st July of 
each calendar year for prevalence or to 1st January of the calendar year specified for 
incidence. The length of data contribution was categorized as 0-3 years, 4-6 years, 7-
9 years, and 10 years or more. Temporal trends in the incidence and prevalence of 
RA were examined using Joinpoints analysis. For this the Joinpoint Regression 
Program was used(25) (See supplementary material).  
The incidence rate of RA for each ten year age-band was calculated in 1994, 2004 
and 2014 to look for the presence of a birth cohort effect. This was stratified by sex. 
Finally, prevalence and incidence of RA were calculated separately for 13 regions in 
the UK for the year 2014 (See supplementary material). To remove the effect of 
different age and gender structures, the prevalence and incidence were standardized 
to the overall CPRD population structure in 2014. Incidence rates were calculated, and 
a likelihood ratio test was performed to find out if there was a statistically significant 
overall geographic variation in the incidence and prevalence. Choropleth maps were 
used to illustrate geographic variations. Data management and analysis were 
performed using Stata software V.13 (Statacorp, Texas, USA). The significance level 





Prevalence and incidence Of the 3,966,443 eligible individuals in 2014, 26,385 
prevalent cases of RA were identified, giving a prevalence (95%CI) of 0.67%(0.66-
0.67). Women had a higher prevalence (0.93%(0.91-0.94)) than men (0.40%(0.39-
0.41)) with age-adjusted rate ratio (95%CI) of 2.08(2.02-2.13). The prevalence of RA 
increased with age (Figure 1A). 
There were a total of 3,413,043 person-years of follow-up in 2014 during which 1299 
incident cases of RA were identified, giving an incidence (95% CI) of 3.81(3.61-4.02) 
per 10,000 person-years. The incidence of RA increased with age (Figure 1B). Women 
had a higher incidence (95% CI) per 10,000 person-years than men (5.09(4.75-5.42) 
vs. 2.51(2.28-2.75)), with an age adjusted IRR (95%CI) of 1.85(1.65-2.07).  
Prevalence and incidence of RA between 1990 and 2014 
In general, crude, age-sex standardised, and age, sex, length of data contributed 
standardized estimates of prevalence of RA increased over time (Table 1, Figure 2). 
The overall annual increase in prevalence was 2.10%(1.5% to 2.70%). However, there 
was one significant joinpoint at 2005 (Figure S1). The prevalence of RA increased by 
3.7%(3.2 % to 4.1%) per-year from 1990 to 2005, and reduced by -1.1%(-2.0% to -
0.2%) per-year from 2005 to 2014.   
The standardised incidence of RA reduced during the study period (Table 2, Figure 
3). On average, the incidence of RA reduced by -1.6%(-0.8% to -2.5%) per year from 
1990-2014. However, there were two significant join points at 1994 and 2002 
respectively (Figure S1). The incidence of RA reduced by -15.7%(-8.4% to -22.4%) 
per year between 1990 and 1994; plateaued between 1994 and 2002 with an annual 
change in incidence of 3.0%(-0.5% to 6.7%); and again reduced by -3.8%(-1.3% to -
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4.3%) per year between 2002 and 2014. As the incidence of RA was significantly 
higher in 1990 and 1991, we re-analysed the data on temporal trends in the incidence 
of RA after excluding data from these two years. Even after this, there was a 
statistically significant reduction in annual incidence of RA of -0.9%(-0.1% to -1.6%) 
per year between 1992 and 2014, and the incidence of RA reduced significantly 
between 2003 and 2014 with an average reduction of -2.6%(-0.6% to -4.6%) per year. 
These findings did not change when the analysis was restricted to participants with a 
3 year period of registration prior to the 1st January of each year (Figure S2).  
Age specific incidence of RA in 1994, 2004 and 2014 The peak age of onset of RA 
remained between 70-80 years in age, and did not change between 1994 and 2014 
(Table 3). Similar findings were observed when data from men and women were 
analysed separately (Table 3).  
Geographic variation in 2014 
There were statistically significant differences in the prevalence and incidence of RA 
throughout the UK (p<0.001), Figure 4. The age-sex standardised prevalence of RA 
was highest in the North East, Yorkshire and Humber, and Northern Ireland. Regions 
with the lowest prevalence of RA were South Central and London. The East Midlands, 
Yorkshire and Humber, and South West were the regions with the highest 






This is the largest study to examine temporal trends in the incidence and prevalence 
of RA. It reports an increase in the point prevalence of RA from 1990 to 2005, but a 
subsequent reduction between 2005 and 2014, and a gradual reduction in its 
incidence over time. It also reports that the peak age of incidence of RA is in the eighth 
decade of life, which has not changed over the past 20 years. In addition, this study 
found evidence of significant geographic variation in the incidence and prevalence of 
RA in the UK. 
There was an increase in the prevalence of RA from 1990 to 2005, but not in 
subsequent years. This finding is contrary to that of a Global Burden of Diseases study 
which reported that the prevalence of RA remained unchanged between 1990 and 
2010(26). However, that was a systematic review of published studies, which would 
have different observation periods for each study; hence it would be difficult to 
determine the temporal change. This contrasts with studies from Ontario, Canada (27), 
and Rochester, USA(13), where the prevalence of RA increased over time, with no 
reduction in recent years. Further research is required to explore factors underlying 
this, but this could include migration and mortality. Findings from several recent 
studies demonstrate that the standardized mortality rate in RA has not improved over 
time despite improvements in the treatment of RA(28-30).  
In our study, the incidence of RA reduced over time. However, it was significantly 
higher in 1990 and 1991 compared to later years despite our taking precautions to 
prevent prevalent cases being classified as incident cases by requiring participants to 
have 12 months of registration prior to being coded as having incident RA. We also 
undertook a sensitivity analysis by specifying a three year prior registration period 
before a participant could be coded to have incident RA. The latter approach did not 
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reduce the significantly higher incidence rate in 1990 and 1991. Thus, we are 
reasonably certain that the high incidence rate in 1990 and 1991 is not related to 
prevalent RA cases being more likely to be coded as incident RA in the early years of 
the CPRD.  
We observed an increase in incidence of RA in the early 2000s. This could be 
explained by the increasing availability of anti-CCP antibody testing in the UK, which 
would allow cases previously coded as having sero-negative inflammatory arthritis or 
inflammatory arthritis to be coded as RA(31). Similarly, the initial NICE approval for 
use of anti-TNF treatments in patients with RA in the year 2000 could have prompted 
rheumatologists to better classify their patients.  
It is noteworthy that the recent 2010 ACR/EULAR criteria for the classification of RA 
did increase the incidence of RA(32). The 2010 ACR/EULAR classification criteria 
allows patients to be classified as RA at an earlier, less severe stage than the 1987 
ACR criteria(33), and allows a greater number of patients with unclassified 
inflammatory arthritis to meet the classification criteria for RA(34). This finding 
suggests that either the incidence of RA has reduced more significantly, and is being 
masked by a change in disease classification criteria, or that physicians are slow to 
adapt to changes in nomenclature and classification systems. We do not believe that 
the reduction in incidence of RA over time is due to exclusion of previous incident 
cases as this phenomenon would have resulted in a reduction in the incidence of other 
diseases such as gout(35) and type 2 diabetes for which the incidence in the CPRD 
has remained stable and risen respectively(36).   
RA is a common complex disease where genetic predisposition (shared epitope(37)); 
constitutional risk factors (obesity(38)); and environmental exposures (smoking) 
interact to cause chronic joint inflammation(39). As the genetic make-up of a 
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population does not change over relatively short periods of time, and the prevalence 
of obesity is increasing(5), the reduction in incidence of RA could be related to 
reducing prevalence of cigarette smoking in the UK. The prevalence of cigarette 
smoking has reduced from 45% in 1974 to 19% in 2013 in the UK, with similar 
reductions in both men and women (http://ash.org.uk/files/documents/ASH_106.pdf). 
The fact that reducing incidence of RA may be related to smoking is further supported 
by the fact that areas with high prevalence of cigarette smoking have high prevalence 
of RA, and vice versa. For example, North East of England, Yorkshire and the Humber, 
Scotland, and Wales have high prevalence both of RA and cigarette smoking, while 
South Central, London and East of England have lower prevalence of RA and lower 
prevalence of cigarette smoking (http://www.ons.gov.uk/ons/dcp171778_386291.pdf).  
However, geographic variation in the prevalence of RA could be related to other 
aetiological changes such as socio-economic deprivation which also co-associate with 
smoking(40). 
This study provides contemporary data on the epidemiology of RA. The prevalence 
and incidence of RA in the UK, and the female predominance reported in this study 
are in accord with the findings of previous epidemiological studies, and provide 
external validity to these findings. We standardized the crude incidence and 
prevalence of RA to the 2014 population structure, and also to the number of years for 
which data were contributed prior to 1st January or 1st July of that year. This reduces 
the possibility of confounding due to changes in population structure over time, and 
events occurring prior to the start of study period. Thus, we are reasonably confident 
that the reduction in incidence of RA over time is a valid finding. 
The main limitations of this study are those inherent in the use of a large consultation 
based database such as the CPRD. However, the accuracy of diagnosis of RA has 
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been validated previously, which minimizes the possibility of incorrect diagnosis. The 
index date reflects the date of allocation of Read codes for RA, and does not reflect 
disease onset, or the date of diagnosis. However, the date of allocation of a Read 
code for RA (which may happen after a hospital letter confirming a diagnosis of RA) 
would be expected to be within a few months of the date of diagnosis, and does not 
invalidate the findings on the temporal trends in the epidemiology of RA over a 25 year 
period. We modified the published Read code list for identifying RA cases to increase 
its face validity. However, we did not perform a sensitivity analysis to examine the 
effects of these changes on the results. We do not think a change in the Read code 
list will alter the findings on temporal trends in epidemiology of RA.  
In summary, the incidence of RA in the UK is decreasing. These data confirm the 
known predilection of RA in women, but contrary to general opinion the peak age of 
diagnosis of RA is in later years. There was UK-wide variation in the incidence and 
prevalence of RA, and further research is required to identify the reasons underlying 
this phenomenon. Further research is also required to examine temporal trends in 
mortality of RA, and to find out if the reduction in incidence of RA is due to reduced 





 The incidence of RA is reducing gradually. 
 The prevalence of RA has reduced recently. 
 There is significant geographic variation in the occurrence of RA in the UK.   
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1994 4021774 0.45 (0.44 - 0.45) 0.47 (0.46-0.48) 0.50 (0.49-0.51) 
1995 4230629 0.46 (0.46 - 0.47) 0.49 (0.48-0.49) 0.52 (0.51-0.54) 
1996 4431788 0.48 (0.47 - 0.49) 0.50 (0.50-0.51) 0.51 (0.51-0.52) 
1997 4591476 0.50 (0.49 - 0.50) 0.52 (0.51-0.52) 0.55 (0.54-0.56) 
1998 4693233 0.51 (0.51 - 0.52) 0.53 (0.53-0.54) 0.54 (0.53-0.55) 
1999 4781898 0.53 (0.52 -0.53) 0.55 (0.54-0.55) 0.55 (0.55-0.56) 
2000 4860654 0.54 (0.54 -0.55) 0.56 (0.56-0.57) 0.59 (0.58-0.61) 
2001 4918467 0.56 (0.56 -0.57) 0.58 (0.58-0.59) 0.62 (0.60-0.63) 
2002 4952188 0.59 (0.58 -0.59) 0.61 (0.60-0.62) 0.61 (0.61-0.62) 
2003 4996092 0.61 (0.60 -0.61) 0.63 (0.62-0.63) 0.67 (0.65-0.68) 
2004 5039357 0.62 (0.62 -0.63) 0.64 (0.64-0.65) 0.69 (0.68-0.71) 
2005 5097746 0.64 (0.63 -0.65) 0.66 (0.65-0.67) 0.76 (0.73-0.78) 
2006 5096933 0.65 (0.64 - 0.66) 0.67 (0.66-0.67) 0.75 (0.72-0.77) 
2007 5092482 0.65 (0.65 - 0.66) 0.67 (0.66-0.68) 0.67 (0.66-0.68) 
2008 5068313 0.66 (0.65 -0.66) 0.67 (0.66-0.68) 0.67 (0.67- 0.68) 
2009 5035895 0.66 (0.65 - 0.67) 0.67 (0.67-0.68) 0.67 (0.67-0.68) 
2010 4946060 0.67 (0.66 -0.67) 0.67 (0.67-0.68) 0.68 (0.67-0.68) 
2011 4821377 0.67 (0.66 - 0.67) 0.67 (0.67-0.68) 0.67 (0.67-0.68) 
2012 4724886 0.66 (0.66 - 0.67) 0.67 (0.66-0.68) 0.67 (0.67-0.68) 
2013 4456895 0.66 (0.65 - 0.67) 0.67 (0.66-0.67) 0.67 (0.66-0.67) 





Table 2: Incidence of RA from 1990-2014 
Year Person-years 
Incidence rate (95% CI) per 10,000 person-years 
Crude 
Age – sex 
standardised1 
Age – sex duration of 
data contributed 
standardised1 
1990 402627 7.67 (6.86-8.58) 7.81 (6.93-8.68) 7.46 (6.22 – 8.70 ) 
1991 772376 5.44 (4.94-5.98) 5.73 (5.17-6.29) 6.46 (4.55 – 8.37 ) 
1992 950289 4.76 (4.34-5.22) 5.01 (4.54-5.48) 4.93 (4.12 – 5.75 ) 
1993 1090675 4.69 (4.30-5.11) 4.83 (4.41-5.25) 4.36 (3.75 – 4.97 ) 
1994 1189540 3.94 (3.60-4.32) 4.02 (3.66-4.39) 3.85 (3.21 – 4.49 ) 
1995 1303325 4.12 (3.79-4.48) 4.38 (4.00-4.75) 3.93 (2.89 – 4.97 ) 
1996 1398690 3.85 (3.53-4.19) 4.02 (3.68-4.36) 3.58 (3.08 – 4.08 ) 
1997 1624108 4.54 (4.23-4.88) 4.62 (4.28-4.95) 4.67 (4.11 – 5.24 ) 
1998 1877971 3.98 (3.71-4.28) 4.01 (3.72-4.30) 4.22 (3.47 – 4.96 ) 
1999 2210469 4.11 (3.85-4.38) 4.23 (3.95-4.51) 3.94 (3.52 – 4.35 ) 
2000 2737196 4.42 (4.18-4.68) 4.61 (4.35-4.87) 4.76 (4.20 – 5.32 ) 
2001 3146122 4.48 (4.26-4.73) 4.61 (4.36-4.85) 4.71 (4.22 – 5.21 ) 
2002 3493910 4.64 (4.42-4.87) 4.76 (4.53-5.00) 4.64 (4.24 – 5.04 ) 
2003 3751801 4.41 (4.20-4.62) 4.60 (4.37-4.82) 4.94 (4.40 – 5.48 ) 
2004 3953837 4.62 (4.41-4.84) 4.80 (4.57-5.02) 5.20 (4.68 - 5.72) 
2005 4112549 4.04 (3.85-4.24) 4.13 (3.94-4.33) 4.25 (3.86 – 4.65) 
2006 4172806 3.92 (3.74-4.12) 3.99 (3.79-4.18) 4.18 (3.77 – 4.58) 
2007 4185156 3.86 (3.68-4.05) 3.97 (3.78-4.17) 3.66 (3.32 – 4.01) 
2008 4226454 3.67 (3.49-3.86) 3.78 (3.59-3.97) 3.52 (3.16 – 3.87) 
2009 4237654 3.92 (3.73-4.11) 3.95 (3.76-4.14) 3.72 (3.39 – 4.06) 
2010 4165240 3.72 (3.54-3.91) 3.75 (3.56-3.93) 3.52 (3.17 – 3.87) 
2011 4076348 3.66 (3.48-3.85) 3.73 (3.54-3.92) 3.62 (3.28 – 3.96) 
2012 4016632 3.67 (3.49-3.87) 3.76 (3.57-3.96) 3.55 (3.20 – 3.90) 
2013 3773084 4.04 (3.84-4.24) 4.06 (3.85-4.26) 3.73 (3.38 – 4.09) 
2014 3413043 3.81(3.61 –4.02) -/- -/- 




Table 3: Incidence of RA by age 1994, 2004 and 2014 
 Incidence rate (95% CI) per 10,000 person-years 
Age (years) 1994 2004 2014 
Overall    
<20 -/- 0.21 (0.11-0.41) 0.08 (0.03 - 0.25) 
≥20 & <30 0.79 (0.45 - 1.39) 1.09 (0.83 - 1.44) 0.81 (0.57 - 1.16) 
≥30 & <40 2.47 (1.85 - 3.30) 2.18 (1.82 - 2.61) 2.09 (1.70 - 2.57) 
≥40 & <50 3.82 (3.02 - 4.83) 3.73 (3.29 - 4.22) 3.48 (3.00 - 4.03) 
≥50 & <60 6.60 (5.41 - 8.04) 6.98 (6.30 - 7.75) 5.95 (5.30 - 6.67) 
≥60 & <70 7.35 (5.99 - 9.00) 10.44 (9.55 - 11.42) 7.41 (6.62 - 8.29) 
≥70 & <80 10.27 (8.47 - 12.45) 12.08 (10.86 - 13.44) 10.27 (9.15 - 11.53) 
≥80 & <90 7.39 (5.36 - 10.20) 11.79 (10.30 - 13.52) 6.97 (5.76 - 8.44) 
≥90 10.81 (5.62 - 20.77) 7.13 (4.55 - 11.17) 3.41 (1.94 - 6.01) 
Female    
<20 -/- 0.41 (0.20 – 0.81) 0.11 (0.03 – 0.45) 
≥20 & <30 1.09 (0.54 - 2.17) 1.80 (1.31 - 2.46) 1.26 (0.83 - 1.89) 
≥30 & <40 3.77 (2.71 - 5.26) 3.16 (2.55 -3.91) 3.34 (2.65 - 4.22) 
≥40 & <50 5.52 (4.18 - 7.28) 5.81 (5.05 - 6.70) 4.99 (4.20 - 5.94) 
≥50 & <60 10.33 (8.25 - 12.93) 9.33 (8.21 - 10.61) 8.32 (7.24 - 9.55) 
≥60 & <70 8.60 (6.62 - 11.18) 13.04 (11.65 - 14.60) 8.96 (7.75 - 10.35) 
≥70 & <80 12.08 (9.56 - 15.27) 14.43 (12.65 - 16.47) 12.20 (10.55 - 14.12) 
≥80 & <90 9.01 (6.30 - 12.88) 14.35 (12.29 - 16.75) 8.50 (6.78 - 10.66) 
≥90 13.85 (7.21 - 26.62) 7.42 (4.47 - 12.31) 3.24 (1.62 - 6.47) 
Male    
<20 -/- 0.04 (0.01 - 0.32) 0.05 (0.01 – 0.38) 
≥20 & <30 0.51 (0.19 - 1.35) 0.46 (0.25 - 0.83) 0.40 (0.20 - 0.81) 
≥30 & <40 1.18 (0.65 - 2.12) 1.24 (0.88 - 1.73) 0.84 (0.53 - 1.34) 
≥40 & <50 2.16 (1.39 - 3.34) 1.72 (1.33 - 2.22) 1.99 (1.52 - 2.61) 
≥50 & <60 2.93 (1.93 - 4.46) 4.70 (3.94 - 5.62) 3.63 (2.96 - 4.47) 
≥60 & <70 6.02 (4.36 - 8.30) 7.81 (6.75 - 9.04) 5.82 (4.86 - 6.98) 
≥70 & <80 7.85 (5.61 - 10.98) 9.25 (7.72 - 11.09) 8.11 (6.71 - 9.80) 
≥80 & <90 4.18 (1.99 - 8.77) 7.35 (5.52 - 9.78) 4.81 (3.36 - 6.88) 
≥90 -/- 6.21 (2.33 - 16.53) 3.82 (1.43 - 10.18) 
 
